 | Box 1
Nature Biotechnology
22, 121 - 122 (2004)
doi:10.1038/nbt0104-121
The Nature Biotechnology 2004 New Year Quiz | | | 
| Answers to Quiz
1. Amgen (Thousand Oaks, CA, USA) appointed H. Christian Fibiger as v.p. and global therapeutics head for neuroscience research. Amylin (San Diego) named Michael Hanley v.p. of discovery research. Antigenics (New York) appointed Renu Gupta senior v.p. of development. FibroGen (S. San Francisco, CA, USA) named Claire J. Lockey as v.p. of regulatory affairs. Genentech (S. San Francisco, CA, USA) named Marc Tessier-Lavigne senior v.p. for research drug discovery. Invitrogen (Carlsbad, CA, USA) appointed Claude Benchimol as senior v.p. of research and development. Lexicon Genetics (The Woodlands, TX, USA) named William E. Heydorn v.p. of preclinical development. Seattle Genetics (Seattle) appointed Douglas E. Williams as senior v.p. for R&D and CSO.
2. Geoffrey Duyk resigned as president of R&D and CSO from Exelixis (S. San Francisco, CA, USA). Vaughn Kailian resigned as vice chairperson at Millennium Pharmaceuticals (Cambridge, MA, USA). Rod Campbell left his position as CFO at Active Pass Pharmaceuticals (Vancouver, BC, Canada). Jean-Pierre Verhassel retired as president of Serono US (Rockland, MA, USA). John Holaday resigned as chairman and CSO of EntreMed (Rockville, MD, USA). Kieran Gallahue resigned his position as president of Nanogen (San Diego).
3. (a) Acusphere (Watertown, MA) $52.5 million; (b) Advancis (Germantown, PA) $60.0 million; (c) CancerVax (Carlsbad, CA) $72.0 million; (d) Genitope (Redwood City, CA, USA) $33.3 million; (e) Myogen (Denver) $70.0 million; (f) NitroMed (Bedford, MA) $66.0 million; (g) Pharmion (Boulder, CO) $84.0 million.
4. (a) UCSF's Genentech Hall was built using $50 million of a settlement between the university and Genentech (S. San Francisco, CA, USA) in a $200 million lawsuit that alleged the company had stolen human growth hormone DNA. (b) In June, Sam Waksal, former CEO of ImClone Systems (New York), was found guilty of insider trading and tax evasion on June 10 without eligibility for parole. (c) In September, Vertex Pharmaceuticals' former employee Andrew S. Marks was charged with insider trading for allegedly selling more than $476,000 in Vertex stock in September 2001 based on "material, nonpublic information concerning the suspension of clinical trials of an anti-inflammatory drug produced by Vertex."
5. The top five dividend-paying stocks and their yields are: Psychemedics (Cambridge, MA, USA) $0.32, 4.0%; Meridian Bioscience (Cincinnati) $0.36 3.6%; ICN Pharm (Costa Mesa, CA, USA) $0.31, 1.8%; Sanofi-Synthelabo (Paris, France) $0.49, 1.6%; and Altana (Bad Hamburg, Germany) $0.86, 1.4%.
6. Corn engineered to increase expression of tocotrienols (vitamin E).
7. PowderJect (Oxford, UK) was acquired by Chiron (Emeryville, CA, USA). Novuspharma (Milan, Italy) was acquired by Cell Therapeutics (Seattle). Ribopharma (Kulmbach, Germany) was acquired by Alnylam Pharmaceuticals (Cambridge, MA, USA). Biogen (Cambridge, MA, USA) merged with Idec Pharmaceuticals (San Diego); Applied Molecular Evolution (San Diego) was acquired by Eli Lilly (Indianapolis, IN, USA). British Biotech (Cambridge, UK) was acquired by Vernalis (Wokingham, UK).
8. GTC Biotherapeutics (Framingham, MA, USA) is developing recombinant human antithrombin III produced in goats. Pharming (Leiden, The Netherlands) is developing Human C1 esterase produced in rabbits; Meristem Therapeutics (Clermont-Ferrand, France) is developing gastric lipase produced in plants. Epicyte (San Diego) is developing a monoclonal antibody fragment produced in plants.
9. MedImmune (Gaithersburg, MD, USA) and Critical Therapeutics (Cambridge, MA, USA) are collaborating on developing antibodies and other drugs targeting inflammatory diseases. Axovan AG (Basel, Switzerland) and Actellion (Allschwil, Switzerland) are collaborating to optimize endothelial target drugs. Chiron (Emeryville, CA, USA) and the Global Alliance for Tuberculosis Drug Development (New York) are collaborating on tuberculosis drug development. Siga (New York) and Innate (Umeá, Sweden) are collaborating on discovering antiinfectives against bacterial biowarfare agents. Medarex (Princeton, NJ, USA) and Pfizer (New York) have a collaboration to develop fully human therapeutic antibodies against undisclosed targets. Structural GenomiX (San Diego) and Eli Lilly (Indianapolis, IN, USA) have a collaboration to solve the crystal structures of a variety of target molecules.
10. San Jose, $12,106,100; San Francisco, $11,935,032; Fairfield County, $10,748,891; Boston, $10,632,657; Nassau/Suffolk Counties, $10,290,838; Shreveport, $8,202,453; Athens, $8,121,568; Sioux Falls, $7,963,262; Montreal, $7,955,000.
11. Etrasorb, Raptiva, Emtriva, Advate, Cubicin, Bexxar, Aldurazyme, Ganite and Xolair received regulatory approvals in 2003.
12. Italy has created Dibit 2, based at the San Raffaele Scientific Institute in Milan. It plans to recruit 500 scientists most from the United States.
13. (a) OncoGenome (Sart-Tilman, Belgium) became OncoMethylome Sciences; (b) Ribozyme Pharmaceuticals (Boulder, CO, USA) became Sirna Therapeutics; (c) Myriad Proteomics (Salt Lake City, UT, USA) became Prolexys Pharmaceuticals; (d) Pyrosequencing AB (Uppsala, Sweden) became Biotage AB.
14. (a) Belgium, Finland, Greece, the Netherlands, Sweden, the United Kingdom; (b) Germany; (c) Austria, Denmark, France, Ireland, Portugal; (d) Belgium, the Netherlands; (e) Italy, Luxembourg, Portugal.
 16. (a) Alteon (Ramsey, NJ, USA) comes from the Latin 'alt' and the Greek 'eon'; (b) Kaleidos Pharma (Seattle) is derived from 'kalos' and 'eidos'; (c) Alnylam Pharmaceuticals (Cambridge, MA, USA); (d) iThemba Labs (Somerset West, South Africa); (e) ProSanos (La Jolla, CA); (f) Avanir Pharmaceuticals (San Diego) is derived from 'avenir.'
17. MAYA uses DNA and deoxyribozymes to play tic-tac-toe. MAYA never loses.
|
|
|
